How many institutions held CCCC - C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share in Q2 2023?

96 institutional investors reported CCCC - C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share for Q2 2023. Use the holders table for investor-level position and value details.

C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CCCC)

Q: What does CUSIP 12529R107 represent in this 13F holders report?

CUSIP 12529R107 is the security identifier for CCCC - C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share used to aggregate holder disclosures.

CUSIP: 12529R107

Q2 2023 13F Holders as of 30 Jun 2023

Type / Class: Equity / Common Stock, par value $0.0001 per share
Shares outstanding: 237,424,242
Total 13F shares: 34,220,399
Share change: -3,195,643
Total reported value: $94,120,957
Put/Call ratio: 6%
Price per share: $2.75
Number of holders: 96
Value change: -$9,383,233
Number of buys: 51
Number of sells: 70

Quarterly Holders Quick Answers

What is CUSIP 12529R107?
CUSIP 12529R107 identifies CCCC - C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2023
Previous quarter: Q1 2023

Recent filing periods for CUSIP 12529R107:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of CCCC - C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
ArrowMark Colorado Holdings LLC	13F	Company	2.7%	6,380,880	$20,035,963	—	31 Mar 2023	13F
WASATCH ADVISORS LP	13F	Company	2.4%	5,716,021	$17,948,306	—	31 Mar 2023	13F
Alain J. Cohen	3/4/5	Director	— class O/S missing	1,805,252	$11,770,243	—	04 Apr 2022	3/4/5
BlackRock Finance, Inc.	13F	Company	1.6%	3,696,742	$11,607,771	—	31 Mar 2023	13F
PRICE T ROWE ASSOCIATES INC /MD/	13F	Company	1.2%	2,875,374	$9,029,000	—	31 Mar 2023	13F
Soleus Capital Management, L.P.	13F	Company	1%	2,387,020	$7,495,243	—	31 Mar 2023	13F
VANGUARD GROUP INC	13F	Company	0.89%	2,112,526	$6,633,331	—	31 Mar 2023	13F
Bain Capital Life Sciences Investors, LLC	13F	Company	0.69%	1,642,210	$5,157,000	—	31 Mar 2023	13F
TCG Crossover Management, LLC	13F	Company	0.53%	1,250,000	$3,925,000	—	31 Mar 2023	13F
Elena Prokupets	3/4/5	Director	— class O/S missing	534,807	$3,486,942	—	27 Sep 2021	3/4/5
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.35%	840,778	$2,640,042	—	31 Mar 2023	13F
STATE STREET CORP	13F	Company	0.33%	774,221	$2,431,054	—	31 Mar 2023	13F
JACOBS LEVY EQUITY MANAGEMENT, INC	13F	Company	0.3%	723,701	$2,272,421	—	31 Mar 2023	13F
AQR CAPITAL MANAGEMENT LLC	13F	Company	0.26%	606,465	$1,904,300	—	31 Mar 2023	13F
CITADEL ADVISORS LLC	13F	Company	0.22%	527,154	$1,655,264	—	31 Mar 2023	13F
TWO SIGMA ADVISERS, LP	13F	Company	0.17%	400,300	$1,256,942	—	31 Mar 2023	13F
NORTHERN TRUST CORP	13F	Company	0.16%	384,604	$1,207,656	—	31 Mar 2023	13F
DIMENSIONAL FUND ADVISORS LP	13F	Company	0.16%	382,216	$1,200,003	—	31 Mar 2023	13F
Nextech Invest Ltd.	13F	Company	0.16%	375,857	$1,180,191	—	31 Mar 2023	13F
Nuveen Asset Management, LLC	13F	Company	0.15%	356,609	$1,120,000	—	31 Mar 2023	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.15%	345,583	$1,085,131	—	31 Mar 2023	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.14%	326,080	$1,024,000	—	31 Mar 2023	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.13%	317,009	$995,408	—	31 Mar 2023	13F
MORGAN STANLEY	13F	Company	0.12%	294,138	$923,594	—	31 Mar 2023	13F
SUSQUEHANNA INTERNATIONAL GROUP, LLP	13F	Company	0.11%	268,067	$841,730	—	31 Mar 2023	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	0.11%	263,264	$826,649	—	31 Mar 2023	13F
PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO	13F	Company	0.08%	197,045	$619,000	—	31 Mar 2023	13F
D. E. Shaw & Co., Inc.	13F	Company	0.08%	194,161	$609,666	—	31 Mar 2023	13F
GSA CAPITAL PARTNERS LLP	13F	Company	0.07%	177,051	$556,000	—	31 Mar 2023	13F
UBS Group AG	13F	Company	0.07%	162,650	$510,721	—	31 Mar 2023	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.06%	153,556	$482,000	—	31 Mar 2023	13F
Bank of New York Mellon Corp	13F	Company	0.06%	151,557	$475,888	—	31 Mar 2023	13F
STATE OF WISCONSIN INVESTMENT BOARD	13F	Company	0.06%	140,432	$440,956	—	31 Mar 2023	13F
Mariner, LLC	13F	Company	0.05%	127,994	$402,000	—	31 Mar 2023	13F
WELLINGTON MANAGEMENT GROUP LLP	13F	Company	0.05%	124,810	$391,904	—	31 Mar 2023	13F
HRT FINANCIAL LP	13F	Company	0.05%	119,612	$375,000	—	31 Mar 2023	13F
Connor, Clark & Lunn Investment Management Ltd.	13F	Company	0.05%	113,893	$357,624	—	31 Mar 2023	13F
MARSHALL WACE, LLP	13F	Company	0.05%	113,236	$355,561	—	31 Mar 2023	13F
PANAGORA ASSET MANAGEMENT INC	13F	Company	0.05%	107,891	$338,778	—	31 Mar 2023	13F
Squarepoint Ops LLC	13F	Company	0.05%	107,632	$337,964	—	31 Mar 2023	13F
JANE STREET GROUP, LLC	13F	Company	0.04%	100,741	$316,327	—	31 Mar 2023	13F
Vienna Powszechne Towarzystwo Emerytalne S.A. Vienna Insurance Group	13F	Company	0.04%	85,000	$266,900	—	31 Mar 2023	13F
MANUFACTURERS LIFE INSURANCE COMPANY, THE	13F	Company	0.03%	81,751	$256,698	—	31 Mar 2023	13F
AMERIPRISE FINANCIAL INC	13F	Company	0.03%	80,135	$251,624	—	31 Mar 2023	13F
Ergoteles LLC	13F	Company	0.03%	79,770	$250,478	—	31 Mar 2023	13F
Adam Crystal	3/4/5	Chief Medical Officer	— mixed-class rows	38,847 mixed-class rows	$250,282	—	30 Jan 2023	3/4/5
PDT Partners, LLC	13F	Company	0.03%	78,523	$246,562	—	31 Mar 2023	13F
Swiss National Bank	13F	Company	0.03%	73,900	$232,046	—	31 Mar 2023	13F
M&T BANK CORP	13F	Company	0.03%	72,000	$226,040	—	31 Mar 2023	13F
Invesco Ltd.	13F	Company	0.03%	69,459	$218,101	—	31 Mar 2023	13F

Institutional Holders of C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CCCC) as of Q2 2023

As of 30 Jun 2023, C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CCCC) was held by 96 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 34,220,399 shares. The largest 10 holders included WASATCH ADVISORS LP, PRICE T ROWE ASSOCIATES INC /MD/, Soleus Capital Management, L.P., MILLENNIUM MANAGEMENT LLC, BlackRock Inc., VANGUARD GROUP INC, Bain Capital Life Sciences Investors, LLC, TCG Crossover Management, LLC, Nantahala Capital Management, LLC, and Aquilo Capital Management, LLC. This page lists 96 institutional shareholders reporting positions in this security for the Q2 2023 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2023 vs Q1 2023 Across Filers

Q1 2023 holders

117

Q2 2023 holders

Holder diff

-21

Investor	Q1 2023 Shares	Q2 2023 Shares	Share Diff	Share Chg %	Q1 2023 Value $	Q2 2023 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.